ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

Blood

Volumn 97, Issue 4, 2001, Pages 1115-1122

  Hershko, C ^a   Konijn, A M ^a   Nick, H P ^a   Breuer, W ^a   Cabantchik, Z I ^a   Link, G ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3,5 BIS(HYDROXYPHENYL) 1,2,4 TRIAZOL 1 YL]BENZOIC ACID; DEFERASIROX; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART MUSCLE CELL; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; IRON STORAGE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0035865702     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.1115     Document Type: Article

References (47)

1. Results of long-term iron chelating therapy
2. Survival of medically treated patients with homozygous β thalassemia
3. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia
4. Iron chelators for thalassaemia
5. CGP 72 670, a new, potent, orally active iron chelator
6. ICL670A: A new, potent, orally active iron chelator
7. Biologic models for studying iron chelating drugs
8. Phenolic ethylenediamine derivatives: A study of orally effective iron chelators
9. Storage iron kinetics. III: Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells
10. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: Studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores
11. IRC11, a new synthetic chelator with selective interaction with catabolic red blood iron. Evaluation in hypertransfused rats and in iron-loaded rat heart in culture
12. Sex difference in the ferritin content of rat liver
13. A simple technique for measuring storage iron concentrations in formalinized liver samples
14. Heart cells in culture: A model of myocardial iron overload and chelation
15. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture
16. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility
17. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction
18. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells
19. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
20. Heart cells in culture: A simple method for increasing the proportion of myoblasts
21. Desferrioxamin-chelatable iron (DCI), a component of serum nontransferrin iron (NTBI) used for assessing iron chelation therapy
22. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
23. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
24. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
25. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
26. Safety profile of the oral iron chelator deferiprone: A multicentre study
27. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
28. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
29. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
30. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
31. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
32. Phenolic ethyl-enediamine derivatives: A study of orally effective iron chelators
33. Results from a phase I clinical trial of HBED
34. Preparation of substituted 3,5-diphenyl-1,2,4-triazoles as pharmaceutical metal chelators
35. 4-[3,4-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: A novel efficient and selective iron(III) complexing agent
36. Iron chelator chemistry
37. A novel oral iron chelator (ICL 670A): Results of a phase I single-dose safety study
38. Determinants of fecal and urinary iron excretion in desferrioxamine treated rats
39. Mechanism of desferrioxamine iron excretion in thalassaemia
40. Rat heart cells in culture: A model of iron toxicity and chelation
41. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: Studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy
42. The ability of orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells
43. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal
44. Combined therapy with deferiprone and desferrioxamine
45. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major
46. Oral iron chelation: A potential role for HBED in combination therapy